z-logo
open-access-imgOpen Access
Promising Immunotherapy Technique
Author(s) -
Mike Fillon
Publication year - 2012
Publication title -
jnci journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djs449
Subject(s) - immunotherapy , medicine , computer science , immunology , immune system
I n a study in the March 2012 Nature Medicine, researchers described a new immunotherapeutic technique that can " teach " immune system killer cells, known as CD8 T cells, and their antigen-presenting instructor cells, to destroy cancer cells. Just as important, the newly trained cells remain vigilant in case the cancer returns. coauthor of the study, " These findings may be useful in T cell–based vaccine design and adoptive T-cell therapy, where potent effec-tor and memory formation are vital for successful eradication of acute and recurrent disease. " Although the immune system can eliminate some cancerous cells, it does not always recognize them as " foreign. " Also, cancer may develop when the immune system breaks down or does not function adequately. Researchers are developing immunotherapeu-tic techniques to repair, stimulate, or enhance the immune system's responses to cancer and other debilitating diseases. G u e v a r a-P a t i n o said that in addition to getting instructions from the antigen-presenting cells, CD8 T cells need assistance from helper T cells to become effective killers. Under " normal " conditions, DNA directs helper T cells to overproduce a specific protein that unleashes the killer T cells' lethal properties. However, these cells are typically repressed in patients with cancer or HIV. Especially in cancer patients, one of a tumor's menacing properties is its ability to prevent killer T cells from eliminating tumors by putting helper T cells into a suppressed stage, limiting their ability to assist CD8 T cells. According to the researchers, this new technique jump-started defective immune systems in immunocompromised mice and in human killer T cells taken from HIV patients. Guevara-Patino said a clinical trial in cancer patients could begin in about 3 years. In the study, a device called a gene gun delivered snippets of DNA into skin instructor cells. The DNA directed the instructor cells to produce specific proteins, which act like molecular keys. When CD8 T cells interact with the instructor cells, the keys unlock the CD8 T cells' killer properties , jump-starting them to seek out and kill pathogens and cancer cells. With this technique , the killer T cells would not need helper T cells, said G u e v a r a-P a t i n o. So even if a tumor were to suppress the helper T cells, the killer T cells could still kill cancer cells. …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom